MedTrace Logo

Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19

NCT04547257 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-04-20

No results posted yet for this study

Summary

Safety and Effectiveness Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the treatment of patients with COVID-19

Conditions

Interventions

DEVICE

Seraph 100

Bloodfiltration with Seraph 100

Sponsors & Collaborators

  • Vivantes Clinic Neukölln

    collaborator OTHER

  • ExThera Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Herwig Gerlach, Prof. · Vivantes Neukoelln Berlin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2027-01-31
Completion
2027-06-30
FDA Device
Yes

Countries

  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04547257 on ClinicalTrials.gov